• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Hua Medicine picks Hong Kong, S.A.R., China for IPO

biospectrumasiaMarch 12, 2018

Tag: IPO , diabetes drug , Hua Medicine

Hua Medicine, the Shanghai based diabetes drug developer, has chosen Hong Kong, S.A.R., China Special Administrative Region of China instead of U.S. for its initial public offering (IPO) for the Asian financial hub makes a push for biotech listings.

The company is working with advisers Goldman Sachs Group Inc., CLSA Ltd. and UBS Group AG on a planned offering in the city this year. The offering could raise as much as $300 million.

Hua Medicine, led by Chen Li, the former chief scientist for China at Roche Holding AG, is running late-stage clinical trials for its oral drug used for the treatment of type 2 diabetes.

Register as Visitor to CPhI China 2018!

Previous:VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

Next:'Cancer is an increasingly important health issue in the APAC region’

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Hua Medicine picks Hong Kong, S.A.R., China for IPO | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Potassium Tripolyphosphate

Potassium Tripolyphosphate
Alpha lipoic acid

Alpha lipoic acid
R-Alpha Lipoic acid

R-Alpha Lipoic acid
cationic liposome DMG-PEG2000丨160743-62-4

cationic liposome DMG-PEG2000丨160743-62-4
24-epi-Calcipotriol

24-epi-Calcipotriol
Dipotassium Phosphate

Dipotassium Phosphate
Siponimod Intermediate

Siponimod Intermediate
LDS-L1 TANGENTIAL FLOW FILTRATION/Liposome dialysis / liposome ultrafiltration

LDS-L1 TANGENTIAL FLOW FILTRATION/Liposome dialysis / liposome ultrafiltration
LIPUSU? (Paclitaxel Liposome Injection)

LIPUSU? (Paclitaxel Liposome Injection)
LIPOSOMAL IRON

LIPOSOMAL IRON

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service